Elicio Therapeutics (NASDAQ:ELTX) Announces Quarterly Earnings Results, Beats Expectations By $0.14 EPS

Elicio Therapeutics (NASDAQ:ELTX) released its earnings results on Thursday. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.14, FiscalAI reports.

Elicio Therapeutics Stock Performance

NASDAQ:ELTX traded up $0.11 on Friday, hitting $1.51. The company’s stock had a trading volume of 756,123 shares, compared to its average volume of 285,067. The company has a current ratio of 2.77, a quick ratio of 2.77 and a debt-to-equity ratio of 1.20. The stock has a fifty day moving average of $1.91 and a two-hundred day moving average of $6.58. The firm has a market capitalization of $40.91 million, a P/E ratio of -0.81 and a beta of 1.64. Elicio Therapeutics has a one year low of $1.25 and a one year high of $16.00.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ELTX. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Elicio Therapeutics in a research report on Tuesday, October 27th. Wall Street Zen raised Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 15th. B. Riley Financial cut their price objective on Elicio Therapeutics to $8.00 and set a “buy” rating for the company in a report on Thursday, September 24th. Finally, HC Wainwright reissued a “buy” rating on shares of Elicio Therapeutics in a research note on Tuesday, August 18th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $15.00.

Elicio Therapeutics Company Profile

Elicio Therapeutics, Inc (NASDAQ: ELTX) is a clinical-stage biotechnology company developing immunotherapies designed to activate the immune system against cancer. The company’s approach is based on its proprietary Amphiphile technology, which is intended to direct vaccine components and immune-stimulating agents to lymph nodes, where important immune responses are initiated.

Elicio’s lead program is ELI-002, a therapeutic cancer vaccine being developed for patients with tumors containing mutations in the KRAS gene.